X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Egyptian Drug Authority approves Sputnik V vaccine for emergency use

Content Team by Content Team
25th February 2021
in News
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia

The Egyptian Drug Authority has approved the Russian Direct Investment Fund’s (RDIF) Covid-19 vaccine, Sputnik V, under the emergency use authorisation (EUA) procedure.

The vaccine derives from a human adenoviral vector-based platform and uses two separate vectors for the two shots in a course of vaccination.

With more than 100 million people, Egypt is the 35th country in the world to approve the vaccine.

Russian Direct Investment Fund CEO Kirill Dmitriev said: “Egypt is the most populated country of the Middle East and the decision of the Egyptian Drug Authority to include Sputnik V in the national vaccine portfolio demonstrates the appreciation of safety and efficacy of the vaccine.

“Sputnik V is now approved in 35 countries around the world and the number of registrations will keep increasing in coming weeks as the Russian vaccine is widely recognised as one of the best in the world.”

Meanwhile, the Sanitary Regulation Agency (Agencia de Regulación Sanitaria, ARSA) of the Republic of Honduras also granted emergency use authorization to Sputnik V.

RDIF noted that Honduras is the 36th country to approve the vaccine.

So far, Sputnik V is approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar.

Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana and Egypt also approved the vaccine.

In a separate development in India, the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) asked Dr Reddy’s Laboratories to submit more immunogenicity and safety data for the Sputnik V vaccine.

This development comes after the company sought EUA for the vaccine.

The committee also reviewed Bharat Biotech’s application for carrying out Phase III clinical trials of its Covid-19 vaccine, Covaxin, on children aged five to 18 years.

It asked the company to present efficacy data of Covaxin on adults from Phase III trials, for considering the application.

Previous Post

Euromed S.A. Celebrates 50 Years of Scientific Discovery and Botanical Extract Manufacturing Excellence

Next Post

UCB and Microsoft expand drug development partnership

Related Posts

Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials
News

NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials

3rd March 2021
DHL expands pharma capabilities in South Africa
News

DHL Express partners with MASkargo to deliver first batch of Covid-19 vaccines to Malaysia

3rd March 2021
Full service: the expertise and efficiency of a one-stop shop
Drug Development

Full service: the expertise and efficiency of a one-stop shop

26th February 2021
Next Post
UCB and Microsoft expand drug development partnership

UCB and Microsoft expand drug development partnership

Latest News

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment
Press Statements

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

16th March 2021
Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Press Statements

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

3rd March 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In